KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam-Reference-Cited by-同舟云学术

KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Di Pilato Vincenzo¹^ORCID,Aiezza Noemi²,Viaggi Valentina³,Antonelli Alberto²⁴^ORCID,Principe Luigi³,Giani Tommaso²⁴^ORCID,Luzzaro Francesco³,Rossolini Gian Maria²⁴^ORCID

Affiliation:

1. Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy

2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

3. Clinical Microbiology and Virology Unit, A. Manzoni Hospital, Lecco, Italy

4. Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy

Abstract

This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of bla KPC-53 , located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively.

Funder

Ministero dell'Istruzione, dell'Università e della Ricerca

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01429-20

Reference19 articles.

1. Klebsiella pneumoniae: an increasing threat to public health

2. Resistance to ceftazidime–avibactam and underlying mechanisms

3. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015–2017)